The support determines the C-terminal functionality of the peptide and influences swelling, loading, and how well a difficult sequence behaves during chain assembly.
Key Takeaways
- The linker chemistry sets whether the final peptide carries a free acid or an amide.
- High loading increases throughput but also raises the local chain concentration, which promotes interchain aggregation on the support.
- For a routine Fmoc synthesis producing a C-terminal amide, a Rink amide resin at moderate substitution is a sensible starting point.
Linker defines the C-terminus
The linker chemistry sets whether the final peptide carries a free acid or an amide. Wang and 2-chlorotrityl resins release acids, while Rink amide and PAL resins produce C-terminal amides, which is often required for bioactive sequences.
Acid-labile versus base-labile
Most Fmoc work uses acid-cleavable linkers compatible with final TFA treatment. Orthogonal linkers that survive TFA allow the protected peptide to be released intact, which is necessary when fragments will be ligated later.
For related mechanism work, see peptide synthesis scale-up.
Loading matters more than it seems
High loading increases throughput but also raises the local chain concentration, which promotes interchain aggregation on the support. Lowering substitution is one of the simplest and most effective interventions for a difficult sequence.
Swelling and solvent compatibility
The resin must swell properly in the coupling solvent or reagents cannot reach the reactive sites. Polystyrene supports swell well in DMF and dichloromethane, while PEG-grafted resins perform better in more polar and aqueous-compatible systems.
Practical defaults
For a routine Fmoc synthesis producing a C-terminal amide, a Rink amide resin at moderate substitution is a sensible starting point. Change one variable at a time when troubleshooting so the effect of each is interpretable.
Experimental Conditions and Practical Setup
Substitution is determined before synthesis begins, because it sets the local chain concentration on the support. For a sequence that has previously aggregated, the first intervention is to lower loading and re-run rather than to change chemistry, since this single variable often resolves a synthesis that fails at moderate length.
Linker choice by desired C-terminus
| Desired terminus | Linker type | Note |
|---|---|---|
| Free carboxylic acid | Wang or 2-chlorotrityl | Standard for acid termini |
| C-terminal amide | Rink amide or PAL | Common for bioactive sequences |
| Protected fragment for ligation | Orthogonal safety-catch | Survives TFA treatment |
| C-terminal thioester | Thioester-generating linker | Required for native chemical ligation |
Practical Notes for the Bench
- Lower substitution when a sequence shows on-resin aggregation.
- Choose the linker to set the required C-terminal functionality.
- Confirm the resin swells adequately in your coupling solvent.
Frequently Asked Questions
How do I get a C-terminal amide?
Use an amide-forming linker such as Rink amide or PAL rather than an acid-labile Wang-type resin.
Why does lowering resin loading help?
It reduces the local concentration of growing chains on the support, which suppresses interchain aggregation.
Can I release a protected peptide?
Yes, with an orthogonal linker that survives TFA treatment, which is required when fragments will be ligated later.
How do I know if the resin is the problem?
If coupling efficiency drops abruptly partway through a synthesis that started cleanly, aggregation is the likely cause. Lowering substitution is the simplest first intervention.
Related Reading
- peptide synthesis scale-up
- solid-phase peptide synthesis
- preparative HPLC peptide purification
- antioxidant peptide mechanisms
- oral peptide bioavailability
References & Further Reading
- Hansen PR et al. Fmoc Solid-Phase Peptide Synthesis. Methods Mol Biol. 2015. PubMed 26424261
- Hansen PR et al. Fmoc Solid-Phase Peptide Synthesis. Methods Mol Biol. 2024. PubMed 38997478
- Alghamdi ZS et al. Solid-Phase Synthesis of s-Tetrazines. Org Lett. 2023. PubMed 37083299
- Peptide literature search on PubMed
- Full-text archive at PubMed Central
- FDA guidance documents on peptide drug products
All material on this page is intended for laboratory research and educational reference only. It is not medical advice, and it does not describe any approved diagnostic or therapeutic use.
Reviewed by Dr. Elena Marchetti, Peptide Chemistry & Analytical Characterization.